By focusing on chemistry rather than biology alone, Actithera is aiming to elevate radiopharmaceuticals from niche applications to standard-of-care contenders.
A domain-specific AI platform enables scientists to generate and test hypotheses faster, helping pharma teams reduce target prioritization timelines from weeks to days.